Brief: Medicenna Commences Enrollment In The Ability-1 Study Combining MDNA11 With Pembrolizumab

Medicenna Therapeutics

09/01/2024 13:06

Jan 9 (Reuters) - Medicenna Therapeutics Corp  MDNA.TO :
    * MEDICENNA COMMENCES ENROLLMENT IN THE ABILITY-1 STUDY
COMBINING
MDNA11 WITH PEMBROLIZUMAB
    * MEDICENNA THERAPEUTICS CORP- MDNA11 CONTINUES TO
DEMONSTRATE
ENCOURAGING SINGLE-AGENT ACTIVITY FROM DOSE ESCALATION PORTION
OF ABILITY-1 STUDY
    * MEDICENNA THERAPEUTICS- MDNA11 WELL TOLERATED WITH NO
DOSE-LIMITING TOXICITIES, VASCULAR LEAK SYNDROME REPORTED IN ANY
OF DOSE ESCALATION COHORTS
    * MEDICENNA THERAPEUTICS CORP- EXPECTS TO REPORT INITIAL
RESULTS
FROM BOTH MONOTHERAPY EXPANSION,COMBINATION ESCALATION ARMS OF
PHASE 2 STUDY IN H1 2024

Source text for Eikon:  ID:nGNX9YlRzZ 
Further company coverage:  MDNA.TO 

 ((Reuters.Briefs@thomsonreuters.com;))